Specially developed for the immunohistochemical detection of TRAIL-R3 in paraffin embedded tissue. Has been shown to detect TRAIL-R3 expressed at endogenous levels in paraffin-embedded tissue in different mammary carcinoma tissues.
Product Details
Alternative Name: | TRAIL receptor 3, DcR1, Death Receptor 1, TRID, CD263, TNFRSF 10C, TNF-related apoptosis-inducing ligand receptor 3, Tumor necrosis factor receptor superfamily member 10C |
|
Clone: | TR3.06 |
|
Host: | Mouse |
|
Isotype: | IgG1 |
|
Immunogen: | Recombinant human TRAIL-R3. |
|
UniProt ID: | O14798 |
|
Gene/Protein Identifier: | 8794 (Entrez GeneID) |
|
Species reactivity: | Human
|
|
Crossreactivity: | Does not cross-react with human TRAIL-R1, -R2 or -R4. |
|
Applications: | Flow Cytometry, IHC (PS), WB
|
|
Recommended Dilutions/Conditions: | Immunohistochemistry (paraffin sections, 20µg/ml) Western Blot (1µg/ml) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Purity Detail: | Protein G-affinity purified. |
|
Formulation: | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
|
Use/Stability: | Stable for up to 1 year after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
|
Shipping: | Blue Ice |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Scientific Background: | TRAIL-R3 has a higher expression in normal tissues than in tumor cell lines. Highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart.TRAIL-R3 is a receptor for the cytotoxic ligand TNFSF10/TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand. |
|
Protocol: | IHC (paraffin sections) TRAIL-R3 specific staining protocol - Incubate sections in 10mM citrate buffer at pH 6.0 and 99°C for 25min. - Block non-specific binding by incubating sections in blocking solution 1 (PBS containing 20mg/ml BSA, 1mg/ml human IgG) for 20min. - Incubate sections overnight at 4°C in blocking solution 1 using 30μg/ml TRAIL-R3 (human), mAb (TR3.06) (Prod. No. ALX-804-667). - Wash sections twice with PBS buffer and blocking solution 2 (20% normal goat serum) for 20min. - After blocking, incubate with secondary antibody for 30min. at room temperature. - Wash twice with PBS buffer. - Incubate with suitable staining (and counterstaining) substrates. |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer: T. M. Ganten, et al.; J. Mol. Med.
87, 995 (2009),
Abstract;
General Literature References
Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease: S. Brost, et al.; Pathol. Res. Pract.
206, 43 (2010),
Abstract;
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatology
45, 649 (2007),
Abstract;
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs: T.M. Ganten, et al.; Clin. Cancer Res.
12, 2640 (2006),
Abstract;
Full Text
Related Products